R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	789.1	1,069	991.48	1,522	361.6	293.82
Trading Asset Securities	930.51	707.61	712.39	-	-	-
Cash & Short-Term Investments	1,720	1,776	1,704	1,522	361.6	293.82
Cash Growth	-0.95%	4.25%	11.93%	321.00%	23.07%	7.20%
Accounts Receivable	307.18	279.37	238.31	222.26	179.76	129.78
Other Receivables	3.86	7.52	7.67	7.29	8.78	7.79
Receivables	311.04	286.89	245.98	229.55	188.54	137.58
Inventory	77.83	65.23	51.26	53.01	43.27	28.67
Other Current Assets	8.36	3.39	5.1	3.75	11.71	13.2
Total Current Assets	2,117	2,132	2,006	1,809	605.11	473.27
Property, Plant & Equipment	55.21	55.58	40.93	52.45	33.75	24.77
Long-Term Investments	33.15	32.78	-	-	-	-
Goodwill	85.6	85.6	0.08	0.08	0.08	0.08
Other Intangible Assets	17.7	19.43	17.93	12.83	17.88	22.96
Long-Term Deferred Tax Assets	10	8.61	7.62	7.28	4.16	2.7
Long-Term Deferred Charges	2.15	2.4	1.04	1.83	2.51	0.98
Other Long-Term Assets	-	-	-	-	13.98	-
Total Assets	2,321	2,336	2,074	1,883	677.47	524.76
Accounts Payable	42.48	50.97	40.87	32.2	-	-
Accrued Expenses	5.01	34.06	32.14	32.89	49.36	47.47
Short-Term Debt	-	55.14	-	-	-	-
Current Portion of Leases	-	8.91	5.99	9.55	7.08	-
Current Income Taxes Payable	9.76	6.91	7.17	4.08	2.86	3.17
Current Unearned Revenue	227.05	235.12	200.42	183.22	150.9	116.94
Other Current Liabilities	70.82	45.39	27.78	18.57	24.24	18.8
Total Current Liabilities	355.12	436.49	314.36	280.52	234.43	186.38
Long-Term Leases	9.23	7.81	2.88	6.13	3.9	-
Long-Term Unearned Revenue	0.71	0.71	-	-	1	1
Long-Term Deferred Tax Liabilities	4.26	4.25	1.76	2.42	0.05	0.06
Other Long-Term Liabilities	25.53	50.83	0.16	0.27	0.28	0.34
Total Liabilities	394.86	500.09	319.17	289.35	239.66	187.78
Common Stock	96.58	96.58	96	60	45	45
Additional Paid-In Capital	1,065	1,057	1,057	1,079	17.71	17.29
Retained Earnings	797.34	717.07	596.05	448.52	359.71	260.47
Treasury Stock	-37.96	-37.96	-	-	-	-
Comprehensive Income & Other	-0.27	-0.08	-0.41	-0.15	0.12	0.07
Total Common Equity	1,921	1,833	1,748	1,588	422.53	322.83
Minority Interest	4.85	3.62	6.24	5.97	15.28	14.15
Shareholders' Equity	1,926	1,836	1,755	1,594	437.81	336.98
Total Liabilities & Equity	2,321	2,336	2,074	1,883	677.47	524.76
Total Debt	9.23	71.86	8.86	15.68	10.98	-
Net Cash (Debt)	1,710	1,704	1,695	1,507	350.62	293.82
Net Cash Growth	4.59%	0.56%	12.50%	329.70%	19.33%	7.20%
Net Cash Per Share	17.98	17.87	21.69	18.33	4.88	4.07
Filing Date Shares Outstanding	95.14	95.14	96	96	72	72.12
Total Common Shares Outstanding	95.14	95.14	96	96	72	72.12
Working Capital	1,762	1,695	1,692	1,528	370.68	286.89
Book Value Per Share	20.19	19.26	18.21	16.54	5.87	4.48
Tangible Book Value	1,818	1,727	1,730	1,575	404.56	299.79
Tangible Book Value Per Share	19.11	18.16	18.02	16.40	5.62	4.16
Buildings	-	14.43	14.43	14.43	-	-
Machinery	-	78.02	57.08	56.03	51.4	47.56

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.